The BLA is based on results from the LEOPOLD clinical trials, which evaluated BAY 81-8973 in adults and children using two- and three-times-per-week prophylaxis dosing regimens. The trials,
The company said that the label has also been updated to include efficacy data from Pfizer’s Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA). The CAPiTA trial showed statistically
The deal will see evaluation of the safety, tolerability and efficacy of Merck’s anti-PD-1 therapy, pembrolizumab (KEYTRUDA in US), in combination with Eisai oncology compounds lenvatinib mesylate (Lenvima)
The company said that Opdivo is the first and only programed death receptor-1 (PD-1) therapy to show overall survival in previously treated metastatic squamous NSCLC. The approval is
The deal strengthens AstraZeneca’s aclidinium respiratory franchise and builds on the acquisition of Almirall’s respiratory portfolio in 2014 by extending the company’s development and commercialization rights into the
Upon effectiveness of the deal, Islet will be granted exclusive rights to remogliflozin in the global territory outside of Japan, Korea, Taiwan, China, and Latin America. As part
Xydalba is approved to treat ABSSSI with a two-dose regimen of 1000 mg followed one week later by 500 mg, each administered over 30 minutes. Actavis executive vice
Start-up procedures have already been started and patient enrolment is expected to be initiated in the second quarter of 2015. Both the parties will jointly conduct the trial
The new deal will allow Anabolic to expand its reach into new licensed healthcare practitioner segments and provide customers with added convenience and services. Emerson Ecologics president and
Under the deal, Blueprint will identify and optimize drug candidates using its kinase-focused drug discovery platform. The company will also conduct all research activities before filing an investigational
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.